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Background: HIV in Chile has a notification rate of 0.01%. Coreceptor antagonists are a family of antiretroviral drugs
that are used with the prior knowledge of patients HIV-1 tropism. Viral RNA-based tropism detection requires a
plasma viral load ≥1000 copies/mL, while proviral DNA-based detection can be performed regardless of plasma
viral load. This test is useful in patients with low or undetectable viral loads and would benefit with a proper
therapy. The aim of this study was to determine the correlation between HIV RNA and proviral genotypic DNA
tropism tests.
Findings: Forty three Chilean patients were examined using population-based V3 sequencing, and a geno2pheno
false-positive rate (FPR) cutoff values of 5, 5.75, 10 and 20%. With cutoff 5.75% a concordance of 88.4% in tropism
prediction was found after a simultaneous comparison between HIV tropism assessment by RNA and DNA. In total,
five discrepancies (11.6%) were found, 3 patients were RNA-R5/DNA-X4 and two were RNA-X4/DNA-R5. Proviral
DNA enabled the prediction of tropism in patients with a low or undetectable viral load. For cutoff 5 and 5.75%
genotypic testing using proviral DNA showed a similar sensitivity for X4 as RNA. We found that the highest
sensitivity for detecting the X4 strain occurred with proviral DNA and cutoff of 10 and 20%. Viral loads were higher
among X4 strain carriers than among R5 strain carriers (p < 0.05).
Conclusions: A high degree of concordance was found between tropism testing with RNA and testing with
proviral DNA. Our results suggest that proviral DNA-based genotypic tropism testing is a useful option for patients
with low or undetectable viral load who require a different therapy.
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Currently there are 26,740 notified HIV cases in Chile
and there is an estimate of 30 new confirmed cases every
week [1]. New classes of antiretroviral drugs have been
developed to control HIV infection among which are
CCR5 coreceptor inhibitors. However, their use requires
a prior tropism test to assess the type of coreceptor used
by the virus and are generally phenotypic [2]. These tests
are very expensive and difficult to perform, thus being
incompatible with routine diagnostic procedures. For* Correspondence: pferrer40@gmail.com
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reproduction in any medium, provided the orthis reason, genotypic viral tropism assays using viral
RNA have been developed [3]. However, RNA-based
genotypic testing is generally restricted to patients with
viral loads ≥1000 copies/mL, thus its use in patients with
low or undetectable viral loads is limited [2]. To over-
come this issue, DNA-based testing has been explored,
supported by the idea that proviral DNA is the genetic
archive containing all previous mutations of the virus
[4]. In fact, several articles about HIV tropism recom-
mend the use of proviral DNA for prediction of HIV
tropism in patients with low o undetectable viral load.
The concordance between RNA and proviral DNA test
range between 74 and 97.6%, depending of the type
and subtype of HIV [5-7]. According to the Europeantd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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determined in each population and country and is par-
ticularly relevant in drug-naive patients, with toxic ef-
fects or for whom antiretroviral therapy (ART) has failed
and a change in treatment is considered [8]. HIV trop-
ism for Chilean patients under ART and virologic failure
has not been reported and it is unknown if the virologic
failure is associated to a particular HIV tropism. We ad-
dressed this issue testing HIV tropism using viral RNA
and proviral DNA simultaneously in 43 patients belong-
ing to the Chilean AIDS Cohort [9]. These patients did
not have previous determination of viral tropism nor
treatment with Maraviroc. Patients were selected accord-
ing to the following inclusion criterion: under ART and
having at least one virologic failure. This work was ap-
proved by the Ethics Committee of the Hospital Clínico
Universidad de Chile. Table 1 shows the epidemiological
and clinical characteristics of this group. In addition, 50
samples were analyzed to estimate the prevalence of R5
and X4 strains among Chilean patients. This group of
patients underwent the same inclusion criterion and
their epidemiological and clinical features were similar
to the first group (Additional files 1: Table S1 and 2:
Table S2).
Viral RNA was extracted from plasma with EasyMag
(Biomerieux). V3 loop of HIV-1 was amplified by One
step RT PCR was performed in triplicate for each sample
then cDNA was used as template for a nested PCR. Total
DNA was extracted from whole blood using QIAamp®
DNA Mini Kit (Qiagen). Nested PCR to amplify V3 loop
of HIV-1 in Proviral DNA also was performed in triplicate
[10]. Each PCR product was sequenced with the Sanger’s
traditional sequencing method using the 3730xl DNA
Analyzer (Applied Biosystems®) in Macrogen Company
(USA). Sequences were analyzed using RECall [11,12].
The approved sequences were used to predict tropism
using geno2pheno (G2P) and a false-positive rate (FPR)
cutoff of 5%, 5.75%, 10% and 20% (Additional file 3: Table
S3) [3,10,13]. We choose G2P over PSSM (Position-
specific scoring matrices) due to that G2P and PSSM have
equal percentage of concordance for subtype B, the most
common in Chile, but G2P has been more used in clinical
routine analysis in the prediction of HIV tropism [14].
Three predictions were obtained for each sample and the
lowest FPR was considered for the overall prediction ofTable 1 Patient# epidemiological and clinical fetures
(n = 43)
Age (Range) 45 (18:70)*
Gender (Male;Female) (34:9)
CD4 count (Cells/mm3) 232 (5;1162)*
Viral load (Log RNA copies/mL) 3.94 (3.08;5.70)*
*Median and Range.
# All patients with HIV clade B.viral tropism. Statistical analysis of data was carried out
with non-parametric testing in the SigmaPlot V10 Soft-
ware. Viral loads were determined with Nuclisens Easy Q
v2.0 (Biomerieux). CD4 lymphocyte counts were per-
formed with BD TruCount™ (Becton Dickinson).
For each sample, the lowest FPR obtained through
RNA was correlated with the lowest FPR obtained
through proviral DNA (Figure 1). The correlation coeffi-
cient (ρ) between both determinations was 0.817 with a
p value of 2.39 × 10-11. The concordance in prediction
between RNA and proviral DNA was 88.4%. Such results
are similar to those found in previous articles [5-7].
When analyzing RNA, 74.4% of patients had R5 tro-
pism and 25.6% had X4 tropism. For proviral DNA,
72.1% showed a R5 tropism and 27.9% had X4 tropism.
The percentage of patients with the same tropism either
determinated by RNA or proviral DNA was 67.4% for
R5/R5 and 20.9% for X4/X4 tropisms. This indicated
that the Proviral DNA test showed a 90.6% (29/32) of
coincidences for R5 tropism and an 81.8% (9/11) for X4
tropism respect to RNA determinated tropism (Table 2).
Using FPR cut-off value of 5.75% and single or triplicate
testing we obtained a similar number of X4 strains indi-
cating that RNA and proviral DNA tests have similar
sensitivity to detect X4 species. In this case, only five
discrepancies (11.6%) were detected: 3 were RNA R5/
DNA X4 and 2 RNA X4/DNA R5. In a previous work,
discrepancies were reported in 4.8% [5]. In order to im-
prove the tropism concordance by RNA and Proviral
DNA, we repeated this analysis using 5, 10 and 20% cut-
off values as FPR, nevertheless we could not achieve
lower values of discrepancies. The comparison between
the numbers of discrepancies obtained at each cutoffFigure 1 Dispersion graph for simultaneous comparison
between results of RNA–based prediction of tropism (x axis)
and proviral DNA–based prediction (y axis) for 43 paired RNA/
DNA samples. Predictions were performed with the geno2pheno
software and results were expressed as false positive rate (FPR;%).
The correlation coefficient was ρ = 0.817 (P = 2.39 × 10-11).
Table 2 HIV tropism prediction
Sample FPR and RNA-based tropism FPR and DNA-based tropism
FPR1 FPR2 FPR3 Tropism* FPR1 FPR2 FPR3 Tropism* Reported results$ Viral load#
1 (−) (−) 0.3 X4 2.4 39.3 31.2 X4 X4 6.95
2 57.1 47.3 57.1 R5 44.2 57.1 57.1 R5 R5 4.90
3 31 31 28.9 R5 28.9 26.2 18.9 R5 R5 3.34
4 1.7 1.7 1.7 X4 0.5 1.7 0.8 X4 X4 4.43
5 (−) (−) 9 R5 16.7 48.9 35.2 R5 R5 3.83
6 (−) (−) 24.6 R5 52.2 (−) 89.3 R5 R5 5.72
7 99.4 99.4 99.4 R5 (−) 78.4 99.4 R5 R5 1.28
8 1.7 1.7 1.7 X4 1.7 19.1 1.5 X4 X4 4.04
9 40.1 44.9 44.9 R5 0.5 50.9 0.2 X4 X4 3.38
10 86.5 86.5 86.5 R5 86.5 86.5 86.5 R5 R5 5.11
11 (−) 8.6 5.3 X4 6.8 9.3 5.7 X4 X4 4.58
12 17.2 17.2 39.4 R5 17.2 13.8 17.2 R5 R5 6.59
13 5.4 5.4 4.7 X4 5 5 5 X4 X4 3.91
14 42.6 33.7 42.6 R5 42.6 24.6 24.6 R5 R5 1.28
15 35.1 35.1 35.1 R5 36.9 33.7 35.1 R5 R5 3.61
16 99.4 (−) 99.3 R5 99.9 99.2 99.9 R5 R5 4.54
17 1.7 1.7 1.7 X4 1.1 2.6 1.1 X4 X4 5.67
18 66 33.7 66 R5 (−) 42.2 66 R5 R5 3.66
19 1.9 2.9 2.9 X4 2.9 (−) 0.5 X4 X4 5.96
20 (−) 45.7 45.7 R5 (−) 48.7 (−) R5 R5 4.41
21 32.2 17.3 15.4 R5 17.9 13.2 19.5 R5 R5 3.26
22 (−) (−) 6.9 R5 10.6 (−) 6.9 R5 R5 4.34
23 31.4 31.4 31.4 R5 (−) 42.2 (−) R5 R5 5.36
24 1.7 1.3 (−) X4 42.2 27.3 6.9 R5 X4 4.86
25 87.1 87.1 87.1 R5 86.2 (−) (−) R5 R5 5.73
26 74.4 (−) (−) R5 13.8 8.1 37.1 R5 R5 1.28
27 67.3 67.3 22.8 R5 48.9 48.9 (−) R5 R5 4.65
28 (−) 28.7 (−) R5 42.2 (−) 12.8 R5 R5 4.23
29 89.1 89.1 89.1 R5 42.2 42.2 (−) R5 R5 4.18
30 62.5 39.6 48.7 R5 42.2 (−) (−) R5 R5 6.28
31 (−) 24.7 (−) R5 1.7 4.7 42.2 X4 X4 4.04
32 44.6 (−) 44.6 R5 75.6 79.9 0.2 X4 X4 5.88
33 41.6 41.6 41.6 R5 41.6 41.6 41.6 R5 R5 5.26
34 16.6 58.7 58.7 R5 15.4 15.7 (−) R5 R5 1.28
35 72.3 72.8 72.3 R5 72.3 72.3 (−) R5 R5 3.23
36 41.6 38.4 (−) R5 57.6 (−) (−) R5 R5 4.30
37 (−) 3.7 (−) X4 20.4 8.1 8.1 R5 X4 3.78
38 51.2 41.6 51.2 R5 28.5 77.6 45.1 R5 R5 3.38
39 23.1 23.1 23.1 R5 23.1 23.1 23.1 R5 R5 3.20
40 1.7 1.7 2.6 X4 1.7 73.1 73.1 X4 X4 5.46
41 (−) (−) 0.9 X4 0.2 2.9 23.1 X4 X4 3.08
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Table 2 HIV tropism prediction (Continued)
42 20.9 20.9 20.9 R5 79.9 9.6 (−) R5 R5 1.28
43 71.5 71.5 71.5 R5 71.5 71.5 71.5 R5 R5 6.59
*Prediction based on the lowest FPR, $ Prediction based on the worst prognosis, #Log (copies/mL), (−) Data not obtained.
Figure 2 Relationship between HIV viral tropism and the
median of the logarithm of viral load. The figure shows the
median of the viral load of carriers of R5 (n = 61) and X4 (n = 30)
strains. The difference in the mean values of the two groups is
greater than would be expected by random; there is a statistically
significant difference between the input groups (P = 0.017).
* = p < 0.05.
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amount of discrepancies. For instance, the increase in
the 10% cutoff eliminates mismatched samples 24 and
37 but produces others in samples 5, 26 and 42 (Table 2).
However, with this analysis we can observe a better
sensibility to detect X4 variants with a cutoff of 10% and
20%. The major difference to detect X4 variants between
RNA and proviral DNA was observed when using FPR
cutoff values of 10 and 20% (Additional files 3: Table S3,
4 and 5).
On the other hand, through an international collabo-
ration known as external quality assessment (EQA), they
established that an adequate performance of DNA-based
testing might not tolerate more than two R5 and one X4
discrepancies [15]. The analysis was done with 20 sam-
ples, and the discrepancies allowed for R5 and X4 were
10% and 5% of the population respectively. The discre-
pancies obtained by us for R5 and X4 were 7% and 4.7%.
Our results are in agreement with the percentage ob-
tained by EQA and are in concordance with the objec-
tives and results of this international study.
We found that using proviral DNA with a FPR cutoff
of 10% and single testing, it was possible to overcome
the sensitivity for detection of X4 variants using RNA
with a triplicate cutoff of 5.75%. This shows that the in-
crement in the cutoff is useful when the tropism test is
performed without replicates. The three FPR values
could not be obtained for all the samples. For RNA,
three FPR values were obtained in 65%, two in 14% and
one in 20.9% of the samples. For proviral DNA, the re-
sults were 62.8%, 25.6% and 11.6%, respectively. When
retested, these samples did not obtain a V3 loop HIV
amplicon or good quality sequences. Similar limitations
have been previously reported in 14% of the analyzed
samples through proviral DNA and in 10% of samples
analyzed through RNA, and failures have not necessarily
been related to low viral loads [16]. In our case the
explanation for such limitations are poor quality RNA
and proviral DNA amplification and sequencing reac-
tions due to primers mismatches, generating low quality
sequences that were not approved by RECall. The
sequences filtered by Recall were not analyzed manually
due to poor quality of chromatograms where we could
observe the same results detected previously. For in-
stance, very short sequences, multiple nucleotide ambi-
guities, or truncated sequences [12]. We will design
different primers that will allow improvement of the se-
quences and we will take more considerations regardingtemperature variations when working with RNA. When
analyzing FPR values by RNA we found a triple coin-
cidence in 14 samples and a doble coincidence in 15
samples. For proviral DNA we obtained 5 samples with
three equal FPR and 9 with two identical FPR values
(Table 2). This suggests that the FPR values obtained
from RNA have a narrower dispersion than those ob-
tained through proviral DNA with a coefficient of varia-
tion (CV) of 0.8995 and 1.0014 respectively. The wider
dispersion experienced by proviral DNA might indicate
that the cellular fraction has a higher concentration of
genetic variants than plasma. This observation had been
suggested by other researchers previously [17-20].
We estimated the sensibility of the genotypic method
to detect X4 variants using RNA or proviral DNA with
single, duplicated or triplicate testing and FPR cutoff
values of 5.75, 10 and 20% [16]. We found that the high-
est sensitivity for detecting the X4 strain occurs with
proviral DNA and cutoff of FPR 20% (Additional files 4
and 5). Interestingly, when we used proviral DNA single
testing and 10% cutoff, we obtained the same results
than using RNA, triplicate and cutoff 5.75%. When we
used proviral DNA and single testing with 5.75% cutoff
we detected X4 strains with lower sensibility than RNA
using single testing and same cutoff (Additional file 4).
This result shows the negative impact of the dispersion
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tion is performed with single testing and a low FPR cut-
off. Our results suggest that is advisable to perform the
assay in triplicate when proviral DNA or RNA and FPR
cutoff between 5-10% are used. Since triplicate testing
increases the likelihood of detecting X4 variants. How-
ever, for cases of prediction with one sequence, by RNA
or proviral DNA, increasing the FPR cutoff to 20% is
recomended [8].
Once the concordance between the RNA and proviral
DNA was established, we estimated the prevalence of
the X4 variants using a total of 93 samples. We found 30
X4 strain (32.3%), 61 R5 variants (65.6%) and 2 (2.2%)
were not reportable. The prevalence found for X4 or R5
strains was similar to previous studies [20]. With a 10 or
20% cutoff, proviral DNA shows a higher sensitivity in
detection of X4 species compared to the use of RNA.
Therefore, proviral DNA is very useful to determine
HIV tropism in cases where low and intermediate viral
load cannot be solved with RNA testing [18-20]. Proviral
DNA is the only available option for patients with un-
detectable viral loads requiring a change of therapy [21].
Nevertheless, proviral DNA should be supplemented
with deep sequencing to increase X4 minority species
detection. Although deep sequencing is not an imme-
diate clinical application, we believe that in a short time
this will be possible and this technology will improve
the prediction of HIV tropism by genotypic methods
[22-24]. Tropism could not be predicted in only two
(2.15%) of the samples with undetectable viral loads.
This is one of the main advantages of the genotypic
method as compared to the phenotypic method in which
up to 25% of non-reportable samples have been des-
cribed [5]. However, a disadvantage of the method based
on genotypic plasmatic viral RNA and standard sequen-
cing is that it can only detect variants when these are
represented in at least 10% of the population. This limi-
tation has been overcome by using proviral DNA and
deep sequencing, as it has allowed more sensitive detec-
tion of X4 minority species. Nevertheless, at moment,
this strategy still has limited application in routine
clinical analysis [22-24]. Alternatively, using standard
sequencing, we could monitor the evolution of viral
tropism in order to identify when R5-X4 switch occurs.
In this way, we can predict the viral tropism in patients
simultaneously with the viral load and CD4 counts, so
that when we can detect the X4 strains, the physician
can change therapy opportunely.
When analyzing the possible association between viral
tropism and viral load, samples classified as X4 were
found to have higher viral loads as compared to R5 sam-
ples (P = 0.017) (Figure 2). We found that patients with
R5 tropism had higher CD4 counts than patients X4
although the difference was not statistically significant(p > 0.05, Additional file 6). This result together with
other previously published, shows that the association
between R5 with a lower CD4 cell count was demon-
strated, suggesting that detection of X4 variants might
be an indicator of poor prognosis for patients recently
confirmed with HIV infection [25]. Moreover, it has
been observed that X4 HIV, but not R5 HIV, is able to
infect hematopoietic stem cells, a fact that may poten-
tially explain low CD4 counts and the poorer prognosis
related to X4 strain [26].
The R5 prevalence found in the present work implies
that in Chile a high percentage of patients with virologic
failure might be eligible for CCR5 antagonist treatment.
This information will have an immediate clinical applica-
tion, since with tropism tests the patients under viro-
logical failure in our country may change their therapy.
The prevalence reported here was similar to values
reported in other studies involving ART-experienced pa-
tients [21,27]. Our results corroborate the high concor-
dance in tropism prediction by proviral DNA and by
RNA demonstrated previously [5-7]. This work is a con-
tribution in the effort to demonstrate the clinical useful
power of the proviral DNA tropism prediction. However,
given the wider dispersion of FPR values of proviral
DNA found in the present study and demonstrated also
by other authors, we consider advisable to continue per-
forming the test in triplicate preferably when FPR 5-10%
cutoff values are used [8,15]. When a single sequence
is available, the FPR cutoff value should be increased
according to European guidelines [8]. Finally, because
HIV-1 X4 strains are related to poor prognosis, we con-
sider very appropriate to perform the tropism test in
patients recently confirmed with HIV infection together
with viral load, CD4 counts and genotyping for tradi-
tional antiretroviral drugs.Additional files
Additional file 1: Table S1. FPR% triplicates, tropism, viral load and
viral subtype form 50 additional patients used for estimate the X4 or R5
prevalence.
Additional file 2: Table S2. Patient# epidemiological and clinical
features of 50 additional samples used for estimate X4 and R5
prevalence. *Median and Range, # All patients with HIV clade B.
Additional file 3: Table S3. Tropism predictions based on RNA and
proviral using different FPR% cut off. (*) Lower FPR obtained from
triplicate analysis. G2P, HIV viral subtype obtained with geno2pheno
(coreceptor) bioinformatics tools.
Additional file 4: Summary of comparison between RNA and
proviral DNA for genotypic prediction tropism, using different FPR
% cut off values and single, duplicate or triplicated testing.
Additional file 5: Comparison of the sensibility for X4 variants
detection by RNA o proviral DNA using different FPR% cut off
values.
Additional file 6: Relation between X4 or R5 tropism and CD4
counts.
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